Episealer® knee implant approved for sale in Italy

Report this content

Episurf Medical (Nasdaq: EPIS B), a pioneer and leader in individualised technologies for painful joint injuries, today announces that the Episealer® knee implants have been registered and approved for sale in Italy. The company is also in the final stages of establishing distribution in the Lombardia region as a first step.   

“We have identified the Italian market as an attractive market, and we have now completed a local regulatory registration process. We have attended industry congresses in Italy, and had Italian visitors at our masterclass in Stockholm in June. There is a genuine interest in our implant technology, and we look forward to offering the Episealer® to Italian surgeons and patients” says Pål Ryfors, CEO, Episurf Medical.    

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.10 CEST on 4 September 2019.